Latest News in the pharma Industry

Research & Development

MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences collaborate on antibody drug development

MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences collaborate on antibody drug development

6 Apr 2016

The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies to combine their expertise in research and development, intellectual property (IP) protection and management, and commercial acumen for more precise and efficient technology transfer.

Read more 
Merck and Pfizer announce first patient treated in Phase III combination study

Merck and Pfizer announce first patient treated in Phase III combination study

5 Apr 2016

First-line study evaluating avelumab in combination with Inlyta (axitinib) compared with Sutent (sunitinib malate) monotherapy in renal cell carcinoma.

Read more 
NDA Group releases data comparing FDA and EMA ahead of annual DIA EuroMeeting in Hamburg

NDA Group releases data comparing FDA and EMA ahead of annual DIA EuroMeeting in Hamburg

5 Apr 2016

In spite of similar approval numbers, the US continue to outpace Europe.

Read more 
Regeneron and Sanofi announce positive dupilumab topline results from two Phase III trials

Regeneron and Sanofi announce positive dupilumab topline results from two Phase III trials

5 Apr 2016

Dupilumab is first systemic therapy to show positive Phase III results in patients with moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease marked by widespread rash, itching and associated psychosocial comorbidities.

Read more 
GSK receives positive CHMP opinion in Europe for Strimvelis, the first gene therapy to treat very rare disease, ADA-SCID

GSK receives positive CHMP opinion in Europe for Strimvelis, the first gene therapy to treat very rare disease, ADA-SCID

4 Apr 2016

The medicine is a stem cell gene therapy created for an individual patient from their own cells which is intended to correct the root cause of the disease.

Read more 
RedHill Biopharma's interim results from Phase IIa PoC study supporting therapeutic potential of RHB-104 in multiple sclerosis

RedHill Biopharma's interim results from Phase IIa PoC study supporting therapeutic potential of RHB-104 in multiple sclerosis

4 Apr 2016

RedHill Biopharma's interim results from Phase IIa proof-of-concept study supporting therapeutic potential of RHB-104 in multiple sclerosis

Read more 
Janssen receives CHMP Positive Opinion for Trevicta recommending approval in EU for maintenance treatment of schizophrenia

Janssen receives CHMP Positive Opinion for Trevicta recommending approval in EU for maintenance treatment of schizophrenia

3 Apr 2016

If approved, Trevica will be the first treatment for schizophrenia to be administered four times a year and will provide the longest dosing interval available for an antipsychotic medication in the EU.

Read more 
Flixabi, an infliximab biosimilar candidate referencing Remicade, receives positive CHMP opinion

Flixabi, an infliximab biosimilar candidate referencing Remicade, receives positive CHMP opinion

2 Apr 2016

Flixabi to be the second anti-TNF biosimilar commercialized and manufactured by Biogen in the EU.

Read more 
Phase III study findings demonstrate treatment with baricitinib results in significant improvements for patients with RA who had inadequate response to biologics

Phase III study findings demonstrate treatment with baricitinib results in significant improvements for patients with RA who had inadequate response to biologics

31 Mar 2016

Pivotal RA-BEACON study published in New England Journal of Medicine.

Read more 
EMA Validates BMS application for Opdivo for the treatment of classical Hodgkin lymphoma patients

EMA Validates BMS application for Opdivo for the treatment of classical Hodgkin lymphoma patients

31 Mar 2016

Opdivo has potential to become first PD-1 inhibitor approved in a hematological malignancy in European Union.

Read more 
SIR-Spheres Y-90 resin microspheres are a well-tolerated alternative to standard therapies for inoperable primary liver cancer, says new UK NICE MIB

SIR-Spheres Y-90 resin microspheres are a well-tolerated alternative to standard therapies for inoperable primary liver cancer, says new UK NICE MIB

31 Mar 2016

Unlike TACE, most patients treated with SIR-Spheres Y-90 resin microspheres usually require only a single treatment.

Read more 
SGS and DiscoverX to collaborate on the qualification and supply of bioassays for biopharmaceutical development

SGS and DiscoverX to collaborate on the qualification and supply of bioassays for biopharmaceutical development

30 Mar 2016

The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures.

Read more